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dominance in ± 97% of cases for the three studied annual risks
of CHD (0.6%, 1.0% and 1.5%) except for Italy, where domi-
nance in ≥95% was seen at annual risks of 1% and 1.5%. CON-
CLUSIONS: Administering low-dose Aspirin to patients with an
annual risk of CHD of ≥1% is signiﬁcantly cost-saving from the
health care payer’s perspective in all countries analysed. Savings
start after one year of treatment.
PCV34
Nationale des Coûts”: National Study of Costs) database of
public sector. The PMSI (“Programme de Médicalisation des Sys-
tèmes d’Information”) is the French equivalent of DRG system.
The GHM (“Groupes Homogènes de Malades”: Homogeneous
Groups of Patients) corresponding to cardiovascular events were
determined from classifying medical procedure (CdAM: “Clas-
siﬁcation Des Actes Médicaux”) and/or from main diagnosis
(ICD 10: International Classiﬁcation of Diseases). The numbers
of hospitalizations were then determined. The most representa-
tive GHM were selected, and associated prices/costs have been
weighted by suitable numbers of hospitalizations in order to
obtain an average price/cost of hospitalization. RESULTS:
Average prices (private sector) and costs (public sector) have
been estimated respectively in private and public sector at €1815
and €1315 for a coronarography, €2704 and €2971 for a coro-
nary angioplasty (€5750 and €5178 with stenting), €14,905 and
€13,119 for an aorto-coronary bypass, €4271 and €4216 for a
myocardial infarction (including procedures), €2967 and €3483
for a cerebrovascular accident, €1799 et €2570 for a transient
ischemic attack, €1589 and €2350 for stable and unstable
angina, €2433 et €3658 for a heart failure. CONCLUSION: It
is difﬁcult to isolate speciﬁc hospital prices/costs of cardiovas-
cular events. Nevertheless those approximations seem to be the
only way to assess these prices/costs, which in addition are likely
to be used in pharmacoeconomic models.
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OBJECTIVES: To evaluate differences between public and
private hospitals in abciximab prescriptions for patients under-
going PCI with coronary artery disease (CAD) in France.
METHODS: Data were collected from the 2002 “PMSI” data-
base (DRG for every patient admitted). To evaluate the total
number of PCI performed for CAD in private and public hospi-
tals, we selected the following DRGs (myocardial infarction,
coronary endoprothesis, and cardiac catheterization) and crossed
them with the following acts performed during PCI (translumi-
nal angioplasty, stent implantation, atherectomy). We computed
the numbers of abciximab prescriptions from the French sales
2002 in each private and public hospitals. RESULTS: In 2002,
96,247 PCI were performed in patients hospitalized for CAD
(52,046 in private setting, 44,201 in public setting). Abciximab
was administered for 7719 and 2327 PCI procedures in public
and private hospitals, respectively. Abciximab was used for only
18% of PCI in public hospitals and 4.5% in private ones,
although, abciximab is the only drug indicated for prevention of
cardiac ischemic complications in patients undergoing PCI and
recognized by French authorities as correlated to a “major
improvement” for these patients. CONCLUSION: The impor-
tant difference in 2002 between public and private sectors can
be mostly explained by different funding systems: global budget
for public hospitals, fee for services, payment per day and low
daily ﬁxed fare for drugs in private hospitals. In France, a new
DRG system of funding, close to the one for proﬁt hospitals was
implemented in public institutions in 2004. Before that, the
results show a clear difference in the recourse to abciximab
between public and private sectors for the same DRGs due to
the difference in ﬁnancing. If nothing happens, it can be foreseen
that the results observed for proﬁt hospitals will be the rule for
public hospitals and patients undergoing PCI could no more
beneﬁt from abciximab.
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OBJECTIVES: This French DRG analysis aimed to obtain esti-
mations of numbers and prices/costs of private and public 
hospitalizations in 2002 for following cardiovascular events:
coronarography, coronary angioplasty, aorto-coronary bypass,
myocardial infarction, cerebrovascular accident, transient
ischemic attack, stable and unstable angina, heart failure.
METHODS: Anonymized databases were used: private and
public PMSI 2002 databases of BAQIMEHP (“Bureau Assurance
Qualité de l’Information Médico-Economique de l’Hospitalisa-
tion Privée”: Quality Assurance Committee of Health Economic
Information of Private Hospitalization) and ENC 2004 (“Etude
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